4.7 Article

Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism

Journal

ANNALS OF NEUROLOGY
Volume 85, Issue 6, Pages 921-926

Publisher

WILEY
DOI: 10.1002/ana.25477

Keywords

-

Funding

  1. Swiss National Science Foundation [31003A_156376]
  2. Marie Curie Actions International Fellowship Program TransCure
  3. NIH T32 grant [GM007748]
  4. NIH [NS066019, MH104318]
  5. Swiss National Science Foundation (SNF) [31003A_156376] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

SLC1A2 is a trimeric transporter essential for clearing glutamate from neuronal synapses. Recurrent de novo SLC1A2 missense variants cause a severe, early onset developmental and epileptic encephalopathy via an unclear mechanism. We demonstrate that all 3 variants implicated in this condition localize to the trimerization domain of SLC1A2, and that the Leu85Pro variant acts via a dominant negative mechanism to reduce, but not eliminate, wild-type SLC1A2 protein localization and function. Finally, we demonstrate that treatment of a 20-month-old SLC1A2-related epilepsy patient with the SLC1A2-modulating agent ceftriaxone did not result in a significant change in daily spasm count. ANN NEUROL 2019;85:921-926.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available